RARE - Ultragenyx logo

Ultragenyx

RARE
Revenue grew 100% of years10Y
Compare RARE Hold

Ultragenyx Pharmaceutical develops and commercializes therapies for rare and ultra-rare genetic diseases. Its key products include Crysvita, Mepsevii, and Evkeeza, while its clinical pipeline features gene therapies for conditions like Sanfilippo syndrome and Wilson disease.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$240today

Score Overview

1 Year
Score
Net Growth-1.98%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth6.53%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.0
Net Growth-29.16%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth104.02%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-138.50%
Net Trend40%
Net Income Consistency
Rev Growthโ€”
Rev TrendEvery year
Revenue Consistency
All Time
Scoreโ€”
Net Growth-7x
Net Trend33%
Net Income Consistency
Rev Growthโ€”
Rev Trend90%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Ultragenyx has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. RARE does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 15.95โ€”
1 Year2025-10-22
$ 33.14-51.87%
5 Years2021-10-22
$ 78.22-79.61%
10 Years2016-10-21
$ 66.40-75.98%
All Time2014-01-31
$ 42.25-62.25%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 716M-$ 586M$ 292M
2025$ 673M-$ 575M$ 693M
2024$ 560M-$ 569M$ 610M
2023$ 434M-$ 606M$ 577M
2022$ 363M-$ 707M$ 747M
2021$ 351M-$ 454M$ 740M
2020$ 271M-$ 186M$ 1.20B
2019$ 103M-$ 402M$ 755M
2018$ 51M-$ 197M$ 459M
2017$ 2M-$ 302M$ 244M
2016-$ 245M$ 498M
2015$ 0.00-$ 145M$ 436M
IPO2014$ 0.00-$ 59M$ 187M
RARE - Ultragenyx logo

Ultragenyx fundamental performance

Between 2020 and 2025, revenue grew from $ 271M to $ 673M and net income went from -$ 186M to -$ 575M. Revenue increased in every one of those 5 years; net income in 2.

Ultragenyx currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Membership

Explore RARE with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies